Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate-Reference-Cited by-同舟云学术

Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate

Published:2019-03-12 Issue:6 Volume:22 Page:1115-1122
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Shin Kichul¹^ORCID,Baek Han Joo²,Kang Young Mo³,Cha Hoon-Suk⁴,Kang Seong Wook⁵,Park Sung-Hwan⁶,Jun Jae-Bum⁷^ORCID,Lee Yun Jong⁸,Choi In Ah⁹^ORCID,Song Yeong Wook¹⁰¹¹^ORCID

Affiliation:

1. Division of Rheumatology; Seoul Metropolitan Government-Seoul National University Boramae Medical Center; Seoul Korea

2. Division of Rheumatology, Department of Internal Medicine; Gachon University Gil Medical Center; Incheon Korea

3. Division of Rheumatology, Department of Internal Medicine; Kyungpook National University Hospital; Daegu Korea

4. Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center; Sungkyunkwan University; Seoul Korea

5. Division of Rheumatology, Department of Internal Medicine; Chungnam National University Hospital; Daejeon Korea

6. Division of Rheumatology, Department of Internal Medicine; Catholic University of Korea, Seoul St Mary's Hospital; Seoul Korea

7. Department of Rheumatology; Hanyang University Hospital for Rheumatic Diseases; Seoul Korea

8. Division of Rheumatology, Department of Internal Medicine; Seoul National University Bundang Hospital; Seongnam Korea

9. Division of Rheumatology, Department of Internal Medicine; Chungbuk National University Hospital; Cheongju Korea

10. Division of Rheumatology, Department of Internal Medicine; Seoul National University Hospital; Seoul Korea

11. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine, Medical Research Institute; Seoul National University; Seoul Korea

Funder

Astellas Pharma

the Korea Healthcare Technology R&D Project

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13521/fullpdf

Reference29 articles.

1. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2016

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

3. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis;Hazlewood;Cochrane Database Syst Rev,2016

4. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial;Kremer;Ann Intern Med,2002

5. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study;Capell;Ann Rheum Dis,2007

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023;Reumatología Clínica;2024-05

2. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023;Reumatología Clínica (English Edition);2024-05

3. Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study;Seminars in Arthritis and Rheumatism;2022-08

4. Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea;Journal of Rheumatic Diseases;2021-10-01

5. Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial;Arthritis Research & Therapy;2021-07-08